Find info on BESPONSA®, an Rx option for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). See risks & benefits. Find the official home page for …

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia …

2024年3月12日 · Besponsa is an antineoplastic biological drug used to treat adults and children aged 1 year and older with a type of blood cancer called CD22-positive B-cell precursor acute …

Find dosing and administration information for BESPONSA® (inotuzumab ozogamicin) on the official HCP website. See risks & benefits.

The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic …

2024年9月17日 · BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 …

BESPONSA (inotuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous administration. Each single-dose vial …

Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL). Besponsa is …

In patients who achieve a CR or CRi, the recommended total dose of BESPONSA is 1.5 mg/m 2 per cycle, administered as 3 divided doses on Day 1 (0.5 mg/m 2), Day 8 (0.5 mg/m 2), and …

BESPONSA™ for injection - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources for Healthcare professionals: BESPONSA™ (inotuzumab …